Hugo Christian Monroy-Ramírez

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK

Ana Sandoval-Rodríguez, Hugo Christian Monroy-Ramírez, Alejandra Meza-Ríos et al. · Hepatology Communications · 2020 · 49 citations · Full text

Quercetin Reverses Rat Liver Preneoplastic Lesions Induced by Chemical Carcinogenesis

Gabriela Torres, Hugo Christian Monroy-Ramírez, Arturo Axayacatl Martínez-Guerra et al. · Oxidative Medicine and Cellular Longevity · 2017 · 36 citations · Full text

Hepatology, Liver-induced Preneoplastic Lesions, Preneoplastic Lesions +14

Alterations in the Nuclear Architecture Produced by the Overexpression of Tau Protein in Neuroblastoma Cells

Hugo Christian Monroy-Ramírez, Gustavo Basurto‐Islas, Raúl Mena et al. · Journal of Alzheimer s Disease · 2013 · 28 citations

Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio

Jorge Antonio Silva-Gómez, Marina Galicia‐Moreno, Ana Sandoval-Rodríguez et al. · International Journal of Molecular Sciences · 2021 · 26 citations · Full text

Hepatocarcinogenesis Prevention, Apoptosis, Pathology +19

Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model

Jorge Gutiérrez‐Cuevas, Ana Sandoval-Rodríguez, Hugo Christian Monroy-Ramírez et al. · Cardiovascular Drugs and Therapy · 2020 · 23 citations

Obesity, Metabolic Syndrome, Cardiovascular Translational Research +9